PC
ADVM

Polar Capital’s Adverum Biotechnologies ADVM Stock Holding History

Polar Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-62,648
Closed -$7.45M – 281
2019
Q2 		$7.45M Buy
+62,648
New +$5.18M 0.07% 208
2018
Q3 		– Sell
-40,000
Closed -$2.12K – 267
2018
Q2 		$2.12K Hold
40,000
– – 0.01% 243
2018
Q1 		$2.32M Buy
+40,000
New +$2.49M 0.02% 242

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Polar Capital's ADVM Position: Q3 2019 in Review

Polar Capital sold out of Adverum Biotechnologies (ADVM) in Q3 2019, closing a stake of 62,648 shares — an estimated $7.45M sold.

Polar Capital first reported a position in ADVM in Q1 2018 and held it in 3 quarters. The position peaked at $7.45M in Q2 2019. 99 funds tracked by Wall St. Rank hold ADVM as of Q3 2019.

  • Polar Capital reported no remaining Adverum Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Polar Capital sold 62,648 Adverum Biotechnologies shares in Q3 2019, an estimated $7.45M.
  • Polar Capital first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 3 quarters.
  • Polar Capital's Adverum Biotechnologies position peaked at $7.45M in Q2 2019.
  • 99 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2019.

Based on Polar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.